Expression-driven reverse engineering of targeted imaging and therapeutic agents

Robert J. Gillies, Victor J Hruby

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Cancer is a particularly daunting disease to treat because, in its most insidious forms, cells are disseminated throughout the body, rendering surgery and local therapies ineffective. Hence, systemic disease must be targeted by its metabolic, physiological or molecular phenotype rather than by its location. Both tumour metabolism and physiology have been exploited to target therapies with some success. There is every reason to expect that these approaches will continue to advance therapies that discriminate tumour metabolism from that of normat tissues. As an alternative, molecular phenotyping (pharmacogenomics) is a relatively new science, and holds great promise for development of novel therapies and approaches. The discipline of pharmacogenomics has, to date, involved segmentation of patients according to their protein expression patterns in order to direct existing therapies to those populations who stand to benefit the most. In this communication, the authors propose a further application of this technology to develop agents that are reverse-engineered to explicitly target a patient's expressed protein patterns.

Original languageEnglish (US)
Pages (from-to)137-139
Number of pages3
JournalExpert Opinion on Therapeutic Targets
Volume7
Issue number2
DOIs
StatePublished - Apr 2003

Fingerprint

Reverse engineering
Metabolism
Tumors
Imaging techniques
Physiology
Surgery
Pharmacogenetics
Proteins
Tissue
Communication
Therapeutics
Neoplasms
Technology
Phenotype
Population

Keywords

  • Cooperative affinity
  • Molecular imaging
  • Multimetric ligands
  • Pharmacogenomics
  • Targeting agents

ASJC Scopus subject areas

  • Molecular Medicine
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Expression-driven reverse engineering of targeted imaging and therapeutic agents. / Gillies, Robert J.; Hruby, Victor J.

In: Expert Opinion on Therapeutic Targets, Vol. 7, No. 2, 04.2003, p. 137-139.

Research output: Contribution to journalArticle

@article{247801082093419584c7d30080d34ab0,
title = "Expression-driven reverse engineering of targeted imaging and therapeutic agents",
abstract = "Cancer is a particularly daunting disease to treat because, in its most insidious forms, cells are disseminated throughout the body, rendering surgery and local therapies ineffective. Hence, systemic disease must be targeted by its metabolic, physiological or molecular phenotype rather than by its location. Both tumour metabolism and physiology have been exploited to target therapies with some success. There is every reason to expect that these approaches will continue to advance therapies that discriminate tumour metabolism from that of normat tissues. As an alternative, molecular phenotyping (pharmacogenomics) is a relatively new science, and holds great promise for development of novel therapies and approaches. The discipline of pharmacogenomics has, to date, involved segmentation of patients according to their protein expression patterns in order to direct existing therapies to those populations who stand to benefit the most. In this communication, the authors propose a further application of this technology to develop agents that are reverse-engineered to explicitly target a patient's expressed protein patterns.",
keywords = "Cooperative affinity, Molecular imaging, Multimetric ligands, Pharmacogenomics, Targeting agents",
author = "Gillies, {Robert J.} and Hruby, {Victor J}",
year = "2003",
month = "4",
doi = "10.1517/14728222.7.2.137",
language = "English (US)",
volume = "7",
pages = "137--139",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Expression-driven reverse engineering of targeted imaging and therapeutic agents

AU - Gillies, Robert J.

AU - Hruby, Victor J

PY - 2003/4

Y1 - 2003/4

N2 - Cancer is a particularly daunting disease to treat because, in its most insidious forms, cells are disseminated throughout the body, rendering surgery and local therapies ineffective. Hence, systemic disease must be targeted by its metabolic, physiological or molecular phenotype rather than by its location. Both tumour metabolism and physiology have been exploited to target therapies with some success. There is every reason to expect that these approaches will continue to advance therapies that discriminate tumour metabolism from that of normat tissues. As an alternative, molecular phenotyping (pharmacogenomics) is a relatively new science, and holds great promise for development of novel therapies and approaches. The discipline of pharmacogenomics has, to date, involved segmentation of patients according to their protein expression patterns in order to direct existing therapies to those populations who stand to benefit the most. In this communication, the authors propose a further application of this technology to develop agents that are reverse-engineered to explicitly target a patient's expressed protein patterns.

AB - Cancer is a particularly daunting disease to treat because, in its most insidious forms, cells are disseminated throughout the body, rendering surgery and local therapies ineffective. Hence, systemic disease must be targeted by its metabolic, physiological or molecular phenotype rather than by its location. Both tumour metabolism and physiology have been exploited to target therapies with some success. There is every reason to expect that these approaches will continue to advance therapies that discriminate tumour metabolism from that of normat tissues. As an alternative, molecular phenotyping (pharmacogenomics) is a relatively new science, and holds great promise for development of novel therapies and approaches. The discipline of pharmacogenomics has, to date, involved segmentation of patients according to their protein expression patterns in order to direct existing therapies to those populations who stand to benefit the most. In this communication, the authors propose a further application of this technology to develop agents that are reverse-engineered to explicitly target a patient's expressed protein patterns.

KW - Cooperative affinity

KW - Molecular imaging

KW - Multimetric ligands

KW - Pharmacogenomics

KW - Targeting agents

UR - http://www.scopus.com/inward/record.url?scp=0037399124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037399124&partnerID=8YFLogxK

U2 - 10.1517/14728222.7.2.137

DO - 10.1517/14728222.7.2.137

M3 - Article

C2 - 12667092

AN - SCOPUS:0037399124

VL - 7

SP - 137

EP - 139

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 2

ER -